We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 606.00 | 5.34% | 11,958.00 | 11,956.00 | 11,962.00 | 12,086.00 | 11,850.00 | 11,890.00 | 1,170,661 | 12:27:51 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.13 | 185.37B |
From Apr 2019 to Apr 2024
By Razak Musah Baba
LONDON--AstraZeneca PLC (AZN.LN) said Friday it had positive results from the Phase III hormonal therapy trial comparing the Faslodex drug to Arimidex in the treatment of breast cancer.
The biopharmaceutical firm said the trial compared Faslodex 500 milligrams with Arimidex 1 milligram for the treatment of locally-advanced or metastatic breast cancer in post-menopausal women who haven't had prior hormonal treatment for hormone-receptor-positive breast cancer.
AstraZeneca said Faslodex was superior to Arimidex and met its primary endpoint of extended progression-free survival.
Aromatase inhibitors such as Arimidex are the current standard of care in first-line treatment for postmenopausal women with advanced HR+ breast cancer.
"The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure. Faslodex has over 10 years of clinical evidence and we are committed to exploring its potential along with the rest of our outstanding oncology portfolio," said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca.
Also Friday, AstraZeneca announced that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL regarding the New Drug Application for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia, a high potassium level in the blood serum, by ZS Pharma, a subsidiary of AstraZeneca.
The CRL refers to observations arising from a pre-approval manufacturing inspection. AstraZeneca and ZS Pharma are evaluating the content of the CRL and will work closely with the FDA to determine the appropriate next steps for the New Drug Application, the company said.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
May 27, 2016 02:43 ET (06:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
